Roche has identified over 150 studies that need to transition to CTR (Clinical Trial Regulation) and has assigned them to specific transition slots. To ensure compliance with published EMA (European Medicines Agency) and CTCG (Clinical Trials Coordination Group) guidelines, internal guidance has been developed. This guidance is regularly reviewed and revised to incorporate any updates to the guidelines. Roche is committed to sharing the entire transition process and all experiences related to it.

Transitioning ongoing Studies from CTD to CTR

DIA Europe 2024 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2024 will be the prime opportunity to discuss how collaboration and innovation can support sustainability in healthcare and each stakeholder’s role in making it happen.

Join us in the vibrant city of Brussels for an unforgettable experience, where the power of collaboration will be on full display to inspire actionable outcomes and mobilise for solutions the life sciences’ community. Witness first-hand the profound impact of united efforts, gain valuable insights from across the drug development lifecycle, and play an active role in shaping the future of the pharmaceutical arena.

DIA Europe 2024

A global, member-driven non-profit organization mobilizing life sciences and healthcare. DIA fosters innovation to improve health and well-being worldwide. Professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.